What is Liquid Biopsy?
Cancer detection and monitoring method
Liquid Biopsy, also known as fluid biopsy, is a significant branch of in vitro diagnosis that is primarily based on blood or other body fluid for disease analysis and monitoring, such as cancer. With a simple blood draw, circulating tumor biomarkers in the blood sample provide information on tumor progression and treatment efficacy, and guiding personalized precision medication direction. Compared with traditional tissue biopsy, liquid biopsy has provided additional benefits of real-time monitoring, avoid unrepresentative sampling in heterogenous tumor, and provides comprehensive clinical information.
Liquid Biopsy is a branch of in vitro diagnostics that analyses and diagnoses diseases such as cancer through the use of body liquids like blood or urine. It was rated as one of the “Breakthrough Technologies 2015” by MIT Technology Review.
Compared to traditional tissue biopsy, liquid biopsy is equipped with unique advantages like real-time monitoring, ability to overcome tumor heterogeneity, and comprehensive diagnostic information. Currently, in clinical researches, liquid biosy mainly includes tests for CTC (Circulating Tumor Cell), ctDNA (Circulating Tumor DNA), exosomes, and Circulating miRNA etc. In comparison to traditional methods like observation of clinical symptoms or diagnostic imaging, using liquid biopsy can predict the risk of cancer earlier, enabling “Early discovery, early screening, early treatment”.
What is Circulating miRNA?
microRNAs or miRNAs are small RNA molecules that are non-coding and have important effects on gene expression, often inhibitory. By binding to mRNAs in the cells, the microRNAs inhibit DNA functioning, thus affecting important life functions in a cell. In many cancer types, miRNAs production is upregulated, converting an ordinary cell into a cancerous one. Additionally, these miRNAs can be transported outside the cell, in the tumour environment, in sacs/vesicles called 'exosomes'. The presence of a high number of exosomal miRNAs has been associated with the spread of certain types of cancer in the body. Isolation and detection of miRNAs from a patient’s blood can help in early cancer diagnosis, without the need for invasive surgeries.
What is Circulating Tumor Cell (CTC)?
Circulating tumor cell (CTCs) are the cancer cells that have detached from the primary tumor or metastatic tumor into circulatory system during tumor progression or metastases. CTC provides comprehensive information of cancer in cellular, genetics and protein levels. Hence, CTC detection is an effective tool for earlier detection, evaluation of therapeutic efficacy, individual precision medicine selection, drug resistance detection, earlier tumor recurrence evaluation and real-time monitoring of cancer.
How can we detect CTCs in blood?
Cellomics CTC detection Platform - New generation of CTC viable Cell Sorting.
The CTC detection platform has employed the leading microfluidic chip technology that select CTCs extensively by cell size, cell shape and multiple surface biomarkers. This technology has combined the physical, chemical and biological properties of CTCs to uphold the high sensitivity, high specificity and high accuracy of CTC detection.
-
12/022020
【創業奇兵】90後女醫生毅然創業 登上福布斯年輕創業家榜單
90後女醫生黃園放棄穩定收入，於2017年毅然創立生物科技公司 - 晶准醫學，開發細胞篩選儀，快速提升癌症檢測速度，讓大眾及時得到治療，近日她更加登上福布斯中國30歲以下精英榜，成為生物醫學界新星。
-
11/102020
福布斯中国发布2020年度30岁以下精英榜
2020年11月9日，福布斯中国推出了最新的30岁以下精英榜（30 Under 30），并选出了300位30岁以下活跃在中国各个领域的优秀青年...
-
09/242020
HK CityU’s Develops Cancer Cell Detection Tech
A biomedical research team at City University of Hong Kong (CityU) has successfully developed ground-breaking technology that can accurately perform early screening for cancer cells and effectively mo
-
09/242020
城大研發出5分鐘癌症檢測技術 準確率逾9成
城市大學團隊研發出以5分鐘完成癌症篩查的技術，只須抽取病人4毫升血液檢查，就可以得出患癌風險及藥物療效，準確率超過9成，是全球同類技術中最快的篩查方法...
-
09/242020
香港研發出精準癌症血液檢測技術：5分鐘分選癌細胞準確率逾九成
香港中通社12月19日電】（記者 黎金良）香港城市大學生物醫學研究團隊19日宣佈，成功研發出精準癌症早期篩查和疾病監測的突破性技術，病人只需透過4毫升血液檢查，5分鐘後即可分選出癌細胞，準確率逾九成。這項新技術可讓病人盡快得知患癌風險，同時監測藥物在治療過程中的療效...
-
09/242020
Five-minute cancer test arrives
Researchers at City University have developed a screening technology that can assess a person's cancer risk with a blood test. It is the fastest test globally - being three to six months faster than c
-
09/242020
城大研發驗癌新技術 抽血檢測僅需 5 分鐘全球最快
癌症是人類頭號殺手之一，如果能及早發現，成功康復的機會可更高。城市大學生物醫學研究團隊公布研發出新的檢測技術，只需抽取病人約 4 毫升血液，便可在約 5 分鐘內可分選出癌細胞，準確率逾 9 成...
-
09/242020
【Hello，未來你好！】科學園吸才助創科 網上招聘獲企業盛讚
香港科技園公司（科技園公司）致力提升本地的創科發展及培育人才，每年都會舉辦以創新及科技為主題之職業博覽，為創科界提供配對平台。今年首次把職業博覽移師網上，於3月25日至4月21日舉行「香港科學園網上職業博覽2020」，並吸引了170間招聘公司於平台上提供超過1,100份職位空缺，包括人工智能及機械人技術 、金融科技、生物醫藥科技及智慧城市等領域...
-
09/242020
城大研究新突破 準確度逾九成 四毫升血五分鐘驗出癌細胞
香港城市大學的生物醫學研究團隊，成功研發出精準癌症早期篩查和疾病監測的突破性技術，病人只需透過四毫升血液檢查，五分鐘後即可分選出癌細胞，準確度逾九成，讓病人盡快得知患癌風險，同時可監測藥物在治療過程中的療效...
-
09/242020
城大新癌症血液檢測技術 驗癌只需4毫升血5分鐘
現時判斷病人是否患上癌症，常見的檢查方法以影像檢測和腫瘤液體活檢法，惟方法耗時，準確率僅50%至60%；城大成功研發癌症血液檢測技術，病人不但只需透過4毫升血液，更可5分鐘後即可分辨出癌細胞，且準確率高達逾九成，亦能夠讓病人提早3至6個月發現癌症，及早治療...
-
09/242020
城大新驗血技術 5分鐘揪出癌細胞 準確度9成 病發前3年已檢測到-
城大生物醫學研究團隊成功研發精準癌症血液檢測技術，只需抽取病人4毫升血液，5分鐘便可篩選出癌細胞，準確率逾9成，提升檢驗便利性，檢測速度是全球最快，更可最早於病發前3年檢測到癌細胞，小至0.1毫米腫瘤亦能發現，料最快半年後在港使用。惟腫瘤科專科醫生表示，「滴血驗癌」僅能作初步檢測，須進一步以影像和抽取組織化驗作檢查...
-
09/242020
城大新血液檢測 5分鐘揪出癌細胞
[本報訊] 香港城市大學研究團隊成功研發精準癌症早期篩查技術，以及疾病監測技術，病人只需透過四毫升血液檢查，五分鐘後即可分選出癌細胞，原理技術為全球最快，準確率逾九成，讓病人盡快得知患癌風險，亦可監測藥物在治療過程中療效...
Product
CTC 100 Sorter
CTC PreDX
CTCMntDX
CTCImmunoDx
About
The Team
Awards
News
Blog
Copyright © 2020 Cellomics All Rights Reserved
Copyright © 2020 Cellomics All Rights Reserved